Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and is known to be associated with a poor prognosis and limited therapeutic options. Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapeutics that have demonstrated efficacy as monotherapy in metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yordanova, Mariya, Hubert, Audrey, Hassan, Saima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709256/
https://www.ncbi.nlm.nih.gov/pubmed/34959671
http://dx.doi.org/10.3390/ph14121270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709256/
https://www.ncbi.nlm.nih.gov/pubmed/34959671
http://dx.doi.org/10.3390/ph14121270

Ejemplares similares